title: Pictilisib stalls advanced ER+/PR+ breast cancer.
mesh_terms: D005260:Female; D006801:Humans; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D058534:Class I Phosphatidylinositol 3-Kinases; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077267:Fulvestrant; D007191:Indazoles / Q000008:administration & dosage; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage
chemical_list: C532162:2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; D058534:Class I Phosphatidylinositol 3-Kinases; D004958:Estradiol; D000077267:Fulvestrant; D007191:Indazoles; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; C484760:PIK3CA protein, human; D047428:Protein Kinase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013449:Sulfonamides